U.S. Markets close in 4 hrs 56 mins
  • S&P 500

    3,608.62
    -29.73 (-0.82%)
     
  • Dow 30

    29,572.24
    -338.13 (-1.13%)
     
  • Nasdaq

    12,094.52
    -111.33 (-0.91%)
     
  • Russell 2000

    1,817.95
    -37.32 (-2.01%)
     
  • Crude Oil

    45.12
    -0.41 (-0.90%)
     
  • Gold

    1,776.80
    -11.30 (-0.63%)
     
  • Silver

    22.37
    -0.27 (-1.19%)
     
  • EUR/USD

    1.1965
    -0.0006 (-0.0479%)
     
  • 10-Yr Bond

    0.8490
    +0.0070 (+0.83%)
     
  • Vix

    22.32
    +1.48 (+7.10%)
     
  • GBP/USD

    1.3342
    +0.0027 (+0.2055%)
     
  • USD/JPY

    104.2500
    +0.1650 (+0.1585%)
     
  • BTC-USD

    19,304.24
    -29.59 (-0.15%)
     
  • CMC Crypto 200

    378.23
    +13.63 (+3.74%)
     
  • FTSE 100

    6,339.51
    -28.07 (-0.44%)
     
  • Nikkei 225

    26,433.62
    -211.09 (-0.79%)
     

Is Avenue Therapeutics (ATXI) Stock Outpacing Its Medical Peers This Year?

Zacks Equity Research
·2 min read

Investors focused on the Medical space have likely heard of Avenue Therapeutics (ATXI), but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.

Avenue Therapeutics is a member of our Medical group, which includes 904 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. ATXI is currently sporting a Zacks Rank of #2 (Buy).

Over the past three months, the Zacks Consensus Estimate for ATXI's full-year earnings has moved 20.81% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.

Our latest available data shows that ATXI has returned about 3.13% since the start of the calendar year. At the same time, Medical stocks have gained an average of 1.53%. This shows that Avenue Therapeutics is outperforming its peers so far this year.

To break things down more, ATXI belongs to the Medical - Drugs industry, a group that includes 173 individual companies and currently sits at #82 in the Zacks Industry Rank. On average, stocks in this group have lost 4.44% this year, meaning that ATXI is performing better in terms of year-to-date returns.

Investors with an interest in Medical stocks should continue to track ATXI. The stock will be looking to continue its solid performance.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Avenue Therapeutics, Inc. (ATXI) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.